Quigley M M, Collins R L, Blankstein J
Department of Gynecology, Cleveland Clinic Foundation, Ohio 44106.
Fertil Steril. 1988 Oct;50(4):562-6. doi: 10.1016/s0015-0282(16)60183-8.
Patients beginning an in vitro fertilization (IVF) treatment cycle were prospectively randomized in double-blind fashion to receive either follicle-stimulating hormone (FSH) (Metrodin, Serono Laboratories, Inc., Randolph, MA) (n = 50) or human menopausal gonadotropin (hMG) (Pergonal, Serono) (n = 48) in combination with clomephene citrate (CC) (Serophene, Serono). There were no statistically significant differences in the percentage of dropped cycles, follicular response as measured by serum estradiol or ultrasound imaging, cycle day for hCG administration, number of oocytes recovered, fertilization and cleavage rates of the recovered oocytes, or the rate of clinical pregnancy establishment. In conclusion, there were no clinically important differences between FSH and hMG when combined with CC for enhanced follicular recruitment for IVF. Therefore, there is no apparent justification for the use of FSH in CC combination regimens, considering FSH's increased cost as compared with hMG.
开始体外受精（IVF）治疗周期的患者被前瞻性地以双盲方式随机分组，分别接受促卵泡激素（FSH）（Metrodin，雪兰诺实验室公司，马萨诸塞州伦道夫）（n = 50）或人绝经期促性腺激素（hMG）（Pergonal，雪兰诺）（n = 48）联合枸橼酸氯米芬（CC）（Serophene，雪兰诺）。在周期取消率、通过血清雌二醇或超声成像测量的卵泡反应、给予hCG的周期日、回收的卵母细胞数量、回收卵母细胞的受精和分裂率或临床妊娠建立率方面，均无统计学显著差异。总之，在IVF中，FSH与hMG联合CC用于增强卵泡募集时，没有临床重要差异。因此，考虑到FSH与hMG相比成本增加，在CC联合方案中使用FSH没有明显的理由。
